YARROW BIOSCIENCE, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
YARROW BIOSCIENCE, INC. (YARW) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$301.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-01.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2024-03-01
- YARROW BIOSCIENCE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-03-31 was $8.24M, a 86.47% decline year-over-year.
- YARROW BIOSCIENCE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-03-31 was $60.95M, a 338.22% increase year-over-year.
- YARROW BIOSCIENCE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2020-03-31 was $13.91M.
- YARROW BIOSCIENCE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2019-03-31 was -$8.89M.
- YARROW BIOSCIENCE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$301.00K.
- YARROW BIOSCIENCE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$11.88M.
- YARROW BIOSCIENCE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was -$15.56M, a 212.51% decline from fiscal 2020.
- YARROW BIOSCIENCE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2020 was $13.83M, a 15.78% decline from fiscal 2019.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$301.00K 10-K · filed 2024-03-01 | |||
| 2022-12-31 | -$11.88M 10-K · filed 2024-03-01 | |||
| 2022-03-31 | $8.24M 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | -$15.56M 10-K · filed 2023-03-14 | |||
| 2021-09-30 | -$5.51M 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $45.59M 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | $60.95M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $13.83M 10-K · filed 2022-03-17 | |||
| 2020-09-30 | $29.23M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $52.78M 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $13.91M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $16.43M 10-K · filed 2021-03-04 | |||
| 2019-09-30 | $12.64M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $11.17M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | -$8.89M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $11.96M 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |